Valganciclovir Hydrochloride Generics Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 450 mg
Reference Brands: Valcyte® (EU & US)
Category:
Nephrology
Valganciclovir Hydrochloride Tablets are antiviral medications used to prevent and treat cytomegalovirus (CMV) infections, especially in kidney transplant patients.it helps reduce the risk of CMV infection in immunocompromised patients.
Valganciclovir Hydrochloride Generics is available in Tablet
and strengths such as 450 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Valganciclovir Hydrochloride Generics is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Valganciclovir Hydrochloride Generics can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Valganciclovir Hydrochloride Tablets are an antiviral medication commonly used in nephrology, particularly in kidney transplant patients. It is primarily prescribed to prevent or treat cytomegalovirus (CMV) infections, which can be a significant risk for those with suppressed immune systems after a transplant. Valganciclovir works by inhibiting the replication of the virus, ensuring better transplant outcomes. Marketed under the brand name Valcyte® in both the US and EU, it is available in tablet form, typically in 450 mg strength. Ideal for Pharma B2B distributors in the nephrology space, Valganciclovir helps support post-transplant care by reducing the risk of viral complications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing